Last reviewed · How we verify
HR20013 for injection;dexamethason — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
HR20013 for injection;dexamethason (HR20013 for injection;dexamethason) — Fujian Shengdi Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HR20013 for injection;dexamethason TARGET | HR20013 for injection;dexamethason | Fujian Shengdi Pharmaceutical Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HR20013 for injection;dexamethason CI watch — RSS
- HR20013 for injection;dexamethason CI watch — Atom
- HR20013 for injection;dexamethason CI watch — JSON
- HR20013 for injection;dexamethason alone — RSS
Cite this brief
Drug Landscape (2026). HR20013 for injection;dexamethason — Competitive Intelligence Brief. https://druglandscape.com/ci/hr20013-for-injection-dexamethason. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab